http://purl.org/np/RAsqd9h62vEr9LmPDdCJGAccvaZ50fOhW1ZO-w1CyKSDY#Head
http://purl.org/np/RAsqd9h62vEr9LmPDdCJGAccvaZ50fOhW1ZO-w1CyKSDY
http://www.nanopub.org/nschema#hasAssertion
http://purl.org/np/RAsqd9h62vEr9LmPDdCJGAccvaZ50fOhW1ZO-w1CyKSDY#assertion
http://purl.org/np/RAsqd9h62vEr9LmPDdCJGAccvaZ50fOhW1ZO-w1CyKSDY
http://www.nanopub.org/nschema#hasProvenance
http://purl.org/np/RAsqd9h62vEr9LmPDdCJGAccvaZ50fOhW1ZO-w1CyKSDY#provenance
http://purl.org/np/RAsqd9h62vEr9LmPDdCJGAccvaZ50fOhW1ZO-w1CyKSDY
http://www.nanopub.org/nschema#hasPublicationInfo
http://purl.org/np/RAsqd9h62vEr9LmPDdCJGAccvaZ50fOhW1ZO-w1CyKSDY#pubinfo
http://purl.org/np/RAsqd9h62vEr9LmPDdCJGAccvaZ50fOhW1ZO-w1CyKSDY
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.nanopub.org/nschema#Nanopublication
http://purl.org/np/RAsqd9h62vEr9LmPDdCJGAccvaZ50fOhW1ZO-w1CyKSDY#assertion
http://purl.obolibrary.org/obo/DOID_1040
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Disease
http://purl.org/np/RAsqd9h62vEr9LmPDdCJGAccvaZ50fOhW1ZO-w1CyKSDY#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
http://purl.obolibrary.org/obo/DOID_1040
http://purl.org/np/RAsqd9h62vEr9LmPDdCJGAccvaZ50fOhW1ZO-w1CyKSDY#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate
https://w3id.org/biolink/vocab/treats
http://purl.org/np/RAsqd9h62vEr9LmPDdCJGAccvaZ50fOhW1ZO-w1CyKSDY#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://identifiers.org/drugbank:DB11581
http://purl.org/np/RAsqd9h62vEr9LmPDdCJGAccvaZ50fOhW1ZO-w1CyKSDY#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement
http://purl.org/np/RAsqd9h62vEr9LmPDdCJGAccvaZ50fOhW1ZO-w1CyKSDY#association
http://www.w3.org/2000/01/rdf-schema#label
venclexta is a bcl 2 inhibitor indicated for the treatment of adult patients with chronic lymphocytic leukemia cll or small lymphocytic lymphoma sll 1 1 in combination with azacitidine or decitabine or low dose cytarabine for the treatment of newly diagnosed acute myeloid leukemia aml in adults who are age 75 years or older or who have comorbidities that preclude use of intensive induction chemotherapy 1 2 venclexta is indicated for the treatment of adult patients with chronic lymphocytic leukemia cll or small lymphocytic lymphoma sll venclexta is indicated in combination with azacitidine or decitabine or low dose cytarabine for the treatment of newly diagnosed acute myeloid leukemia aml in adults who are age 75 years or older or who have comorbidities that preclude use of intensive induction chemotherapy this indication is approved under accelerated approval based on response rates see clinical studies 14 2
http://purl.org/np/RAsqd9h62vEr9LmPDdCJGAccvaZ50fOhW1ZO-w1CyKSDY#association
https://w3id.org/biolink/vocab/association_type
https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation
http://purl.org/np/RAsqd9h62vEr9LmPDdCJGAccvaZ50fOhW1ZO-w1CyKSDY#association
https://w3id.org/biolink/vocab/provided_by
https://w3id.org/um/NeuroDKG
http://purl.org/np/RAsqd9h62vEr9LmPDdCJGAccvaZ50fOhW1ZO-w1CyKSDY#association
https://w3id.org/biolink/vocab/relation
https://schema.org/TreatmentIndication
https://identifiers.org/drugbank:DB11581
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Drug
http://purl.org/np/RAsqd9h62vEr9LmPDdCJGAccvaZ50fOhW1ZO-w1CyKSDY#provenance
http://purl.org/np/RAsqd9h62vEr9LmPDdCJGAccvaZ50fOhW1ZO-w1CyKSDY#assertion
http://www.w3.org/ns/prov#wasAttributedTo
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAsqd9h62vEr9LmPDdCJGAccvaZ50fOhW1ZO-w1CyKSDY#pubinfo
http://purl.org/np/RAsqd9h62vEr9LmPDdCJGAccvaZ50fOhW1ZO-w1CyKSDY#sig
http://purl.org/nanopub/x/hasAlgorithm
RSA
http://purl.org/np/RAsqd9h62vEr9LmPDdCJGAccvaZ50fOhW1ZO-w1CyKSDY#sig
http://purl.org/nanopub/x/hasPublicKey
MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB
http://purl.org/np/RAsqd9h62vEr9LmPDdCJGAccvaZ50fOhW1ZO-w1CyKSDY#sig
http://purl.org/nanopub/x/hasSignature
UEAodeV68hw8mC0CA6OgsSqxZQZRTXb+6gmGO9dfLB1kL/GQiP7A1d/m92QNaUFzkYSGce7Llgcsk7J0QfDGuiPTljXHtd1J/T3Uvy4ALnnPOI3F4qj6zEXjVBhIFIlNGX7XFZqsncHHvXkTHl3mzmvoirZMuelsfM8rUEgyhHQ=
http://purl.org/np/RAsqd9h62vEr9LmPDdCJGAccvaZ50fOhW1ZO-w1CyKSDY#sig
http://purl.org/nanopub/x/hasSignatureTarget
http://purl.org/np/RAsqd9h62vEr9LmPDdCJGAccvaZ50fOhW1ZO-w1CyKSDY
http://purl.org/np/RAsqd9h62vEr9LmPDdCJGAccvaZ50fOhW1ZO-w1CyKSDY
http://purl.org/dc/terms/created
2021-06-12T12:28:30.662+02:00
http://purl.org/np/RAsqd9h62vEr9LmPDdCJGAccvaZ50fOhW1ZO-w1CyKSDY
http://purl.org/dc/terms/creator
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAsqd9h62vEr9LmPDdCJGAccvaZ50fOhW1ZO-w1CyKSDY
https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate
http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM
http://purl.org/np/RAsqd9h62vEr9LmPDdCJGAccvaZ50fOhW1ZO-w1CyKSDY
https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate
http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM
http://purl.org/np/RAsqd9h62vEr9LmPDdCJGAccvaZ50fOhW1ZO-w1CyKSDY
https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate
http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs